ZURA BIO LIMITED Investment Income, Interest
ZURA BIO LIMITED (ZURA) reported Investment Income, Interest of $1.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- ZURA BIO LIMITED investment income, interest for the quarter ending 2026-06-30 was $1.92M, a 11.82% increase year-over-year.
- ZURA BIO LIMITED investment income, interest for the quarter ending 2026-03-31 was $1.32M, a 27.41% decline year-over-year.
- ZURA BIO LIMITED investment income, interest for the quarter ending 2025-12-31 was $1.28M, a 39.98% decline year-over-year.
- ZURA BIO LIMITED investment income, interest for the quarter ending 2025-09-30 was $1.53M, a 37.99% decline year-over-year.
- ZURA BIO LIMITED investment income, interest for fiscal 2025 was $6.34M, a 20.78% decline from fiscal 2024.
- ZURA BIO LIMITED investment income, interest for fiscal 2024 was $8.00M, a 265.87% increase from fiscal 2023.
- ZURA BIO LIMITED investment income, interest for fiscal 2023 was $2.19M, a 383408.77% increase from fiscal 2022.
- ZURA BIO LIMITED investment income, interest for fiscal 2022 was $570.00.
| Period end | Investment Income, Interest 1 month | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 7 month | Investment Income, Interest 9 month | Investment Income, Interest 10 month | Investment Income, Interest 11 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.92M 10-Q · filed 2026-08-11 | $3.24M 10-Q · filed 2026-08-11 | $4.51M derived: sum of 3 quarters · filed 2026-08-11 | $6.04M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $1.32M 10-Q · filed 2026-05-07 | $2.60M derived: sum of 2 quarters · filed 2026-05-07 | $4.12M derived: sum of 3 quarters · filed 2026-05-07 | $5.84M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $2.80M derived: sum of 2 quarters · filed 2026-03-19 | $4.52M derived: sum of 3 quarters · filed 2026-08-11 | $6.34M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $1.53M 10-Q · filed 2025-11-13 | $3.24M derived: sum of 2 quarters · filed 2026-08-11 | $5.06M 10-Q · filed 2025-11-13 | $7.19M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $1.72M 10-Q · filed 2026-08-11 | $3.53M 10-Q · filed 2026-08-11 | $5.66M derived: sum of 3 quarters · filed 2026-08-11 | $8.12M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $1.82M 10-Q · filed 2026-05-07 | $3.94M derived: sum of 2 quarters · filed 2026-05-07 | $6.40M derived: sum of 3 quarters · filed 2026-05-07 | $8.60M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.59M derived: sum of 2 quarters · filed 2026-03-19 | $6.78M derived: sum of 3 quarters · filed 2026-03-19 | $8.00M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $2.46M 10-Q · filed 2025-11-13 | $4.66M derived: sum of 2 quarters · filed 2025-11-13 | $5.87M 10-Q · filed 2025-11-13 | $7.24M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $2.20M 10-Q · filed 2025-08-14 | $3.41M 10-Q · filed 2025-08-14 | $4.78M derived: sum of 3 quarters · filed 2025-08-14 | $5.60M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $1.22M 10-Q · filed 2025-05-08 | $2.58M derived: sum of 2 quarters · filed 2025-05-08 | $3.40M derived: sum of 3 quarters · filed 2025-05-08 | $3.40M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.19M derived: sum of 2 quarters · filed 2025-03-25 | $2.19M derived: sum of 3 quarters · filed 2025-03-25 | $2.19M 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | $815.00K 10-Q · filed 2024-11-07 | $815.00K derived: sum of 2 quarters · filed 2024-11-07 | $816.00K 10-Q · filed 2024-11-07 | $816.29K derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.00K 10-Q · filed 2024-08-13 | $1.29K derived: sum of 3 quarters · filed 2024-08-13 | $1.51K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-09 | $1.29K derived: sum of 2 quarters · filed 2024-05-09 | $1.51K derived: sum of 3 quarters · filed 2024-05-09 | $1.56K derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $290.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $514.00 derived: sum of 2 quarters · filed 2023-03-28 | $556.00 derived: sum of 3 quarters · filed 2023-03-28 | $8.00K 10-K · filed 2024-03-28 | $570.00 10-K · filed 2023-03-28 | |||
| 2022-09-30 | $224.00 10-Q · filed 2022-11-14 | $266.00 derived: sum of 2 quarters · filed 2022-11-14 | $280.00 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $42.00 10-Q · filed 2022-08-12 | $56.00 10-Q · filed 2022-08-12 | ||||||
| 2022-03-31 | $14.00 10-Q · filed 2022-05-13 | |||||||
| 2021-12-31 | $51.00 10-K · filed 2023-03-28 | |||||||
| 2021-09-30 | $29.00 10-Q · filed 2022-11-14 | $29.00 10-Q · filed 2022-11-14 | ||||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |